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Abstract 
CYP2C19 genotype-guided antiplatelet therapy following percutaneous coronary intervention is 
increasingly implemented in clinical practice.  However, challenges such as selecting a testing platform, 
communicating test results, building clinical decision support processes, providing patient and provider 
education, and integrating methods to support the translation of emerging evidence to clinical practice 
are barriers to broad adoption.  In this report, we compare and contrast implementation strategies of 12 
early adopters, describing solutions to common problems and initial performance metrics for each 
program.  Key differences between programs included the test result turnaround time and timing of 
therapy changes which are both related to CYP2C19 testing model and platform used.  Sites reported 
the need for new informatics infrastructure, expert clinicians such as pharmacists to interpret results, 
physician champions, and ongoing education. Consensus lessons learned are presented to provide a 
path forward for those seeking to implement similar clinical pharmacogenomics programs within their 
institutions.   
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Introduction 
Cytochrome p450 2C19 (CYP2C19) genotyping for antiplatelet therapy selection after percutaneous 
coronary intervention (PCI) is one of the leading clinical pharmacogenomics implementation scenarios in 
the United States.1 Consensus standard-of-care pharmacotherapy post-PCI consists of dual antiplatelet 
therapy with aspirin and a P2Y12 receptor inhibitor, namely clopidogrel, prasugrel, or ticagrelor.2 
Clopidogrel still remains the most commonly prescribed due to lower cost, better accessibility, and 
lower risk of non-coronary artery bypass graft major bleeding compared to newer agents.3-5  
Clopidogrel is a prodrug that requires bioactivation to an active metabolite for therapeutic effect. 
Although multiple enzymes are involved in clopidogrel metabolism, only genetic variation in CYP2C19 
has been consistently associated with alterations in clopidogrel pharmacokinetics and 
pharmacodynamic responses.6-8 CYP2C19 loss-of-function alleles that produce a nonfunctional enzyme, 
now described as nonfunctional alleles by the Clinical Pharmacogenetics Implementation Consortium 
(CPIC),9 are common occurring in approximately 30% of Europeans, 30% of Africans, and 60% of 
Asians.10 Retrospective analyses of clinical trial and patient registry data have shown that compared with 
clopidogrel-treated individuals with two functional alleles of CYP2C19, similarly-treated patients carrying 
at least one nonfunctional allele have an increased risk of cardiovascular events after PCI.11,12 Clinical 
outcomes during treatment with the third generation P2Y12 inhibitors prasugrel and ticagrelor are 
unaffected by CYP2C19 genotype.13,14 
The Food and Drug Administration added a boxed warning to the clopidogrel labeling in 2010 stating 
that clopidogrel effectiveness is reduced in CYP2C19 poor metabolizers (PMs), who have two no-
function variant alleles, and alternative treatments should be considered in these patients.15 CPIC 
guidelines recommend alternative therapy in PMs as well as intermediate metabolizers (IMs), who have 
a single nonfunctional allele; however, they do not address whether the test should be routinely 
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performed.10 Joint guidelines for PCI by the American Heart Association (AHA) and American College of 
Cardiology (ACC) state that CYP2C19 genetic testing, and tailoring antiplatelet therapy based on the 
result might be considered in high-risk patients; however, these guidelines recommend against the 
routine clinical use of genetic testing for PCI patients, based on the absence of data from large 
randomized controlled trials.2 Since the publication of these guidelines, recent data from the IGNITE 
(Implementing GeNomics in PracTice) Network (www.ignite-genomics.org) demonstrate that among 
patients genotyped at the time of PCI, there is a lower risk of major adverse cardiovascular events in 
patients with a CYP2C19 nonfunctional allele treated with prasugrel or ticagrelor compared with 
nonfunctional allele carriers treated with clopidogrel.16 
A number of institutions now clinically test for CYP2C19 genotype in patients undergoing PCI, with 
more institutions likely to follow. Challenges that arise when offering a pharmacogenomic test include 
the selection of a testing platform, communication of test results, developing clinical decision support 
(CDS), patient education, and methods to support the translation of emerging evidence to clinical 
practice.  We have gathered strategies to address these challenges from early adopters of genotype-
guided antiplatelet therapy. The purpose of this paper is to summarize pathways to operationalizing 
CYP2C19 genotype-guided antiplatelet therapy and approaches to overcome key obstacles likely to arise 
during this implementation.  
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Results 
Baseline institutional landscape and CYP2C19 implementation planning 
Twelve large academic institutions in the IGNITE Network Pharmacogenetics Working Group that 
had implemented CYP2C19 genotype-guided antiplatelet therapy after PCI are included in this analysis 
(Table 1).1  CYP2C19–clopidogrel was the first clinical pharmacogenomic implementation launched at 9 
of the 12 institutions.  The University of Illinois at Chicago had previously implemented 
CYP2C9/VKORC1–warfarin pharmacogenomic testing17,Vanderbilt University had launched the PREDICT 
program that focused on six gene–drug pairs, including CYP2C19–clopidogrel18, and Sanford Health had 
launched the Imagenetics program that tested eight pharmacogenes, including CYP2C19.19 
The majority of programs were designed primarily as clinical versus research implementations (7 of 
12 programs) with all but one of these submitting bills to third-party payers or patients for test 
reimbursement.  Program oversight involved multiple collaborating stakeholders led by a formal 
precision medicine group at 9 of 12 institutions. Individual champions, including pharmacists, the cardiac 
catheterization laboratory director, and cardiology or primary care providers, led initiatives at the 
University of Illinois at Chicago, University of North Carolina at Chapel Hill, and Sanford Health, 
respectively.  Program development time varied considerably across institutions and ranged from 6 to 
24 months. 
CYP2C19 targeted populations, ordering procedures, and testing 
Eight of 12 institutions employed a reactive genotype testing model, in which the test was ordered 
in response to a PCI procedure with test results available soon after to guide antiplatelet medication 
therapy. In these instances, the indication for CYP2C19 testing generally included all patients undergoing 
PCI, with some sites further focusing on higher-risk populations (i.e., presence of acute coronary 
syndrome (ACS) or high-risk anatomical features). Four institutions implemented a preemptive model 
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with CYP2C19 testing performed in advance of any immediate need for test results. These programs 
used a predictive model to identify targeted populations with high probability of future PCI or 
clopidogrel use.  Regardless of the testing model, all institutions included inpatients and outpatients 
[patients undergoing elective procedures with short (<24 hour) hospitalization stays] in their study 
populations.   
The size of the target patient population varied considerably among sites based on cardiac 
catheterization laboratory PCI volume. Some research-based programs focused on narrow populations, 
with exclusion criteria applied based on research aims. CYP2C19 test ordering processes for sites with 
clinical implementation programs varied. The majority of programs (5 of 7 sites) depended on a 
prescriber to select CYP2C19 test on the post-PCI order set (opt-in), with the remainder incorporating a 
pre-selected test order on the post-PCI order set so that all patients undergoing PCI were genotyped 
unless the test was deselected (opt-out). 
CYP2C19 assay and reporting methodologies are shown in Table 2.  All tests were performed using 
validated laboratory developed tests in College of American Pathologists/Clinical Laboratory 
Improvement Amendment (CAP/CLIA)-certified laboratories as necessary for performing testing within 
clinical care. Genotyping was performed using a variety of platforms, with all institutions testing and 
reporting allele-defining variants for *2, *3, and *17 at minimum.  All but three institutions had 
protocols to allow for biobanking of genetic samples as part of the implementation program (either to 
an institutional biobank or as part of a research-based implementation). 
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Communication of results, approach to therapy modification, and education strategies 
All institutions reported CYP2C19 test results in the electronic health record (EHR).  Results were 
documented in the “laboratory results” section of the EHR, often as discrete genotype and phenotype 
results (e. g. CYP2C19 *1/*2 and CYP2C19 Intermediate Metabolizer, respectively) with a linked text-
based full report (9 of 12 sites).  At three institutions, the patient genotype or phenotype was also 
recorded on the perpetual patient “problem list” (Table 3).  The laboratory report included CYP2C19 
genotype and predicted phenotype (metabolizer status) without patient-specific genotype-guided drug 
recommendations at 11 of 12 institutions (Indiana University provided a drug therapy recommendation 
on the laboratory report).   
A variety of different methods were used to communicate test results to providers and patients 
(Figure 1).  Institutions with clinical implementation models generally relied on pharmacists or dedicated 
teams/services to provide genotype-informed drug therapy recommendations. Institutions with 
primarily research testing models also included study staff in this process. Four institutions relied solely 
on CDS or messaging for therapeutic recommendations and only Vanderbilt University used interruptive 
CDS delivered immediately after the test result. Eight of 12 sites provided downstream alerting or CDS 
triggered with future clopidogrel orders within the EHR. Three programs actively reported test results to 
downstream providers outside of their institution (e.g., a letter with the test result was sent to the 
primary care practitioner or cardiologist). Three programs routinely provided patients with their test 
results via a letter/report, patient web portal, an “ID” card with genotype results, and/or personal 
communication.  Nine programs (including one of the above that also provided patients with their test 
results) introduced patients to CYP2C19 testing through in-person education and/or disseminated 
brochures, pamphlets, or flyers.  Although a number of provider education strategies were used, 
focused discussions with providers or in-services were perceived by most sites as being the most 
effective strategies.  
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Performance metrics 
Median length of hospital stay for genotyped patients was one day (range 1-3 days) across all 
institutions. Testing process metrics and phenotype frequencies are provided in Table S1. Median 
genotype turnaround time (TAT), defined as each institution’s median time from genotype order to 
result appearing in the EHR, varied widely among institutions, from very short (1 to 5 hours with rapid 
testing platforms such as Spartan RX), to 1-3 days with standard single-gene test platforms in reactive 
models (GenMark eSensor XT-8 or custom Taqman® assays), to longer (6 to 8 days) for those institutions 
who used preemptive panel-based or send-out testing strategies.  Real-world CYP2C19 phenotype 
frequencies were similar across all sites, and consistent with those reported in clinical studies and 
established guidelines.16 All institutions followed CPIC guidelines that recommend alternative therapy 
(prasugrel or ticagrelor) for CYP2C19 IMs or PMs, and clopidogrel for CYP2C19 normal, rapid, and 
ultrarapid metabolizers (*1/*1, *1/*17, and *17/*17 genotypes, respectively). 10 Triple dose clopidogrel 
(225 mg/day) was rarely used.16 
Eight of 12 institutions provided data on downstream medication use for 1858 total patients who 
underwent genetic testing. Figure 2 depicts the proportions of patients with and without nonfunctional 
alleles who were on alternative therapy at time of discharge from the hospitalization associated with 
genetic testing and at the first follow-up appointment after discharge. Overall, 48.0% and 75.5% of IMs 
and PMs, respectively, were on alternative therapy at first follow-up. At the five institutions using 
testing strategies with >1 day TAT (“Standard Testing”: University of Pittsburgh, University of Florida 
Health - Shands Hospital, University of North Carolina at Chapel Hill, University of Illinois at Chicago, and 
Indiana University), a significantly higher proportion of nonfunctional allele carriers (PMs/IMs) were 
receiving alternative therapy at the first follow-appointment versus at time of discharge (58% vs 38%, p 
< 0.0001), whereas the proportion remained consistent (~19%) among those without a nonfunctional 
allele at these same institutions.  This is in contrast to the institutions that used rapid testing solutions 
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(University of Pennsylvania, University of Alabama at Birmingham, and University of Florida – 
Jacksonville) where similar proportions remained on alternative therapy across time-periods. The time 
from PCI to alternative antiplatelet therapy in patients with a nonfunctional allele occurred in less than 1 
day at sites with rapid testing and in a median of one to 10 days at institutions with standard single-gene 
or panel-based testing, respectively.  Notably, the proportion of nonfunctional allele carriers on 
alternative therapy at first follow-up in the standard testing group (58%) was similar to the proportion of 
nonfunctional allele carriers on alternative therapy at discharge (56%) and at first follow-up (54%) in the 
rapid testing groups, respectively.  The proportion of nonfunctional allele carriers on alternative therapy 
at first follow-up varied widely across institutions, ranging from 13% to 100%.   Use of alternative 
therapy in patients without a nonfunctional allele was low, ranging from 19% to 30% in both testing 
groups. 
Implementation challenges 
Sites reported multiple implementation challenges (Table 4), including obtaining provider and 
stakeholder support, establishing hospital contracts for testing equipment, creating laboratory reports, 
and building CDS systems. Logistical challenges were also commonly reported and involved sample 
processing, return of results to providers and patients, and timing of therapy modifications.  Some 
specific challenges varied according to testing strategy and implementation model used. For example, 
the length of time before changes in antiplatelet therapy were made after PCI was an issue for 
institutions that did not use a rapid testing platform, while institutions using rapid testing platforms 
were challenged by the requirement to run testing assays within an hour of sample collection with the 
Spartan RX platform, storage of temperature sensitive testing reagents, and the need to recollect 
approximately 10% of samples for repeat genotyping due to initial sample failure.  For research models, 
operationalizing the study design and patient recruitment difficulties were reported as barriers to 
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implementation. Provider acceptance of clinical recommendations based on CYP2C19 genotype and 
reimbursement for preemptive testing were identified as specific challenges in clinical models.  
Lessons learned 
Table 5 lists the top lessons learned from clinical implementation of CYP2C19 testing reported across 
sites. In the authors’ experience, clinical pharmacogenomics implementation programs require a 
physician champion and multidisciplinary engagement from key stakeholders.  If a pre-emptive testing 
strategy is planned, developing a clear definition of the targeted testing population ahead of time is 
crucial to success. Education efforts need to be deployed early and on an ongoing basis to both 
implementing clinicians and to providers at all levels including nurses, nurse practitioners, pharmacists, 
physicians, and laboratory medicine personnel. Establishing close working relationships with informatics 
groups to create test orders, return and store genetic test results appropriately, and build tailored CDS 
alerts was also deemed critical to achieve program success and sustainability.  Early adopters also 
emphasized the value of having a designated person or team to act on results and in particular, clinical 
pharmacists, to provide interpretation and increase adherence to genotype-informed drug therapy 
recommendations.  Finally, the opportunity to share experiences and learn from leaders at other sites 
who were building similar programs and the availability of guidelines/scientific data (e.g., CPIC, 
PharmGKB) were also valued. 
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Discussion 
CYP2C19 genotype-guided antiplatelet prescribing after PCI is increasing in large academic medical 
centers across the U.S. and beyond. Although early experiences with CYP2C19 testing have been 
reported,18,20-25 the current data provide a unique opportunity to compare and contrast features of 12 
implementation programs. Similarly, the specific challenges faced by program leaders and lessons 
learned in overcoming these obstacles provide a valuable perspective for those seeking to implement 
similar pharmacogenomics programs within their institutions.     
While several different testing platforms were used among institutions in our study, all sites used in-
house testing solutions within CAP/CLIA laboratories versus outsourcing to a commercial laboratory.  
The CYP2C19 *2, *3, and *17 alleles were consistently tested, and the CPIC guideline phenotype 
translation tables were used across all institutions. Nearly all sites using clinical models submitted bills to 
third party payers for reimbursement.  These similarities in the way testing was set up, despite being 
independent decisions at each site, suggests these approaches may be broadly applicable to institutions 
designing new programs. Further, emerging data showing frequent reimbursement across multiple 
payers26 and cost-effectiveness of genotype testing at the time of PCI support this strategy.27 
A simple metric of implementation program success is whether therapy changes were made 
following pharmacogenomic testing. Data on the frequency of alternative therapy prescribing at first 
follow-up in patients with and without a CYP2C19 nonfunctional allele (55-60% versus 20-25%) illustrate, 
as expected, that genotype results were routinely interpreted and used to guide antiplatelet therapy 
selection.  Differences in alternative therapy prescribing frequencies within PMs and IMs (75.5% versus 
48.0%, respectively) at first follow-up further indicate a result predicted PM phenotype was acted upon 
more frequently. Moreover, implementation performance metrics were specific to testing model, and 
platform such that the timing of expected therapy changes was consistent with each institution’s testing 
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TAT.  For instance, implementation models that employ rapid testing solutions observed similar rates in 
alternative therapy use in nonfunctional allele carriers at discharge and follow-up, indicating that these 
sites often accomplished therapy changes prior to discharge. The Spartan RX system (Spartan 
Biosciences, Ottawa, ON) offers advantages in terms of a rapid TAT; however, centers utilizing this 
method observed a re-testing rate of up to 10%. In contrast, sites that used standard single-gene and 
platform-based tests often reported genotype TAT that exceeded patient length of stay for PCI, and had 
a lower frequency of alternative therapy use in PMs/IMs at discharge. Although frequency of alternative 
therapy use at first follow-up was similar to sites with rapid testing, the logistics of achieving drug 
therapy modifications based on genotype after patient discharge is more difficult.  Challenges in re-
establishing contact with the patient, communication with additional providers, and changing drug 
therapy regimens, especially when patients have already received an initial prescription for clopidogrel, 
can complicate the care process.  Furthermore, the impact of the delay in therapy changes on clinical 
outcomes remain unclear. However, it should be assumed that delays in changes of antiplatelet therapy 
in nonfunctional allele carriers may be associated with an increase in risk of acute and subacute stent 
thrombosis. Preemptive genotyping has the noted advantage of avoiding the concerns of test result TAT, 
but adds challenges with timely identification of which patient populations are likely to be prescribed 
drugs impacted by targeted variants.28  Similarly, reimbursement may be a bigger obstacle within 
preemptive testing models.29 Overall, while it is evident that therapy modifications were accomplished 
following testing, the considerable variability in the proportion of nonfunctional allele carriers on 
alternative therapy at first follow-up across sites (13-100%) underscores the complexity of integrating 
genetic results with patient-specific clinical factors and challenges of implementing genotype-guided 
algorithms in clinical practice. 
There was near consensus among sites that return of results to the EHR should include discrete data 
variables such as the gene tested, genotype, and predicted phenotype versus scanned “paper” reports 
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or only free text.  The availability of consensus nomenclature determined by the CPIC term 
standardization project and common dictionaries will likely further encourage the use of standardized, 
interoperable terminology.9  Together, discrete results and standardized terms represent the current 
gold standard for driving CDS. The use of the laboratory reports section of the EHR was ubiquitous, but 
only a few sites stored results in a “problem list” or another location to make the data persistent beyond 
the current patient encounter. Partnering with hospital informatics at the outset of the clinical 
implementation program to establish these requirements, streamline clinical workflows, and maintain 
consistent practices beyond the initial implementation period was deemed crucial.  While a few sites did 
post testing results to web portals or provided genotype cards, few actively returned results to patients 
or to downstream providers outside of the institution.  This remains a future opportunity to further 
leverage pharmacists and for services optimization to improve patient care transitions and adherence to 
protocols. It will also be important to assess patients’ understanding of pharmacogenomics and their 
overall experience with return of test results, as these factors may influence medication adherence and 
can be used to develop educational materials to assist patients who undergo pharmacogenomic testing 
in the future.30 
The summary data and reported lessons learned indicate that a dedicated clinician or team to 
receive the genotype test results is advantageous. This makes sense given the test reports from the 
laboratory rarely included specific therapy recommendations. Personnel with expertise in 
pharmacogenomics such as pharmacists and formal clinical pharmacogenomics services are being used 
to bridge the gap between pharmacogenomic test ordering and medication selection.17,31-33 In the 
current analysis, five sites specifically integrated clinical pharmacy experts to receive results,make 
recommendations, or educate patients and providers.  As programs grow and are scaled to other sites, 
dedicated clinical services and/or an increased reliance on CDS may be expected.  
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The need of a physician champion and persistent, ongoing education was reported as both a 
challenge to overcome and a lesson learned.  Program leaders thought a champion and active 
dissemination approaches such as in-services to be critical to the launch and ongoing success of the 
implementation, test adoption, and adherence to genotype guided recommendations. Ongoing 
education may be especially important in academic and other centers where resident physicians and 
other trainees rotate through the cardiac catheterization laboratory. Genetic literacy is highly variable 
across providers and is understood to influence pharmacogenomic testing adoption.34,35  Educational 
strategies have been reviewed elsewhere36 and their importance should not be undervalued.  
As with any new research protocol or clinical program, there is an inherent inefficiency in being an 
early adopter.  Whether it was through NIH networks such as IGNITE, eMERGE, or the 
Pharmacogenomics Research Network; professional societies; or even direct communication; program 
leaders emphasized the value they found in collaboration and learning from others working to overcome 
common challenges. To help catalyze efforts, by institutions involved in this work are available in the 
IGNITE Network SPARK Toolbox at www.ignite-genomics.org. 
Ultimately, decisions to develop a CYP2C19 genotype-guided prescribing program and its design are 
driven by clinical evidence of value of these services. Recent guidelines state a preference for alternative 
therapy over clopidogrel in patients with ACS treated with PCI based on clinical trial data showing 
improved outcomes with prasugrel and ticagrelor over clopidogrel in this setting, albeit at an increased 
bleeding risk.2 However, approximately 30% of clopidogrel-treated patients in these ACS trials would 
have had a nonfunctional CYP2C19 allele and reduced response to clopidogrel, as has been 
demonstrated in post-hoc genetic sub-studies.12,14,37-39 Even with increased use of alternative therapies 
early after PCI, there remains an argument that genotyping has an important role in informing chronic 
antiplatelet therapy. In particular, clopidogrel may be more appropriate for a patient with a normal 
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metabolizer phenotype and when the patient could not afford or tolerate one of the newer agents.  
Prasugrel and ticagrelor are also commonly prescribed in patients with stable coronary artery disease 
undergoing PCI, even though these agents are only indicated for ACS and there are no randomized 
clinical trial data showing evidence of superiority of alternative therapy in non-ACS indications. Clinical 
guidelines do not endorse use of alternative therapy after PCI for stable coronary artery disease, yet a 
finding of a nonfunctional allele in patients with stable coronary disease prescribed clopidogrel may 
provide support the use alternative therapy in these cases.2 Recent real-world data suggest clopidogrel 
still remains the most commonly prescribed antiplatelet agent after PCI and that there may be a role for 
genotyping in this scenario.5,16 Among patients with genotype results available early after PCI, initiation 
of alternative antiplatelet therapy over clopidogrel in those with a nonfunctional CYP2C19 allele resulted 
in a significant reduction in major adverse cardiovascular events.16 These data and similarly positive 
results from other clinical implementation studies and small randomized controlled trials may prompt 
others to move toward a genotype-guided approach to prescribing antiplatelet therapy in the PCI 
setting.20-23,26,40   
Several limitations to the analysis should be noted.  Selection bias is possible as all institutions were 
recruited from a common research network and approaches to implementation may therefore be 
similar for this reason.  Similarly, while most institutions were university hospitals, the experience at 
Sanford Health indicates that implementation is feasible and well-accepted within a large group of 
private multispecialty practices. As genotype-based prescribing is further expanded to more diverse or 
non-academic settings, preemptive testing or rapid genotyping platforms may be considered so that 
results are available at the time of or soon after PCI.  In the current analysis, Data availability was also 
not consistent as not all sites tracked medication prescribing downstream of the genetic testing, and the 
number of eligible patients who were not genotyped was not recorded as a metric of algorithm use.  
Future work will focus on collecting these data, as well as the sustainability of genotype testing and 
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genotype-guided medication selection over time, to understand which program features are necessary 
to drive optimal prescribing.  Finally, findings may be specific to pharmacogenomics implementation in 
the PCI population and may not be broadly applicable to other populations. 
Overall, clinical implementation of CYP2C19 genotype-guided antiplatelet prescribing after PCI is 
becoming increasingly common. Data and experiences from 12 early-adopter institutions presented 
herein provide real-world insight for institutions seeking to implement genotype-guided antiplatelet 
therapy, and strategies to overcome barriers likely to be encountered. Similarly, lessons learned may be 
applicable to clinical pharmacogenomics implementation efforts for additional gene-drug pairs and to 
genomic medicine more broadly. 
 
Methods  
Our goal was to summarize and compare implementation experiences of early adopters of CYP2C19 
pharmacogenomic testing to guide antiplatelet medication selection.  The study population included 12 
large academic institutions within the IGNITE Network Pharmacogenetics Working Group (five funded 
institutions and seven affiliate members)1 who have tested 6340 patients for CYP2C19 alleles (see Table 
S1 for a breakdown by site).  
Data collection was completed at each site through a structured electronic spreadsheet 
disseminated to each site leader. Specific data elements were selected and definitions were refined 
through open discussions at several in-person meetings and conference calls from September 2016 to 
May 2017. The tool was then pilot-tested for feasibility prior to dissemination to all sites.  Areas of focus 
included the baseline genetics testing landscape at each site, stakeholder involvement, the design of 
each implementation program, testing approaches, informatics setup, return of results procedures, and 
any education provided. Eight of the 12 sites also provided data on antiplatelet medication use after 
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genotyping (1858 total patients). Data cleaning was accomplished iteratively through direct follow-up 
communications. All data elements collected were reported. 
Program performance metrics including testing turnaround times, reported predicted phenotype 
frequencies, and drug prescribing patterns were also sought from local EHRs or research study data 
sources when available.  All data abstraction and reporting was approved by local institutional review 
board at each site.  Descriptive statistics were reported by institution and proportions of patients with 
specific test results prescribed alternative therapy were compared using chi square testing.  Finally, 
common challenges that must be overcome and recommendations (lessons learned) for those 
considering similar implementations in the future were solicited from site investigators and aggregated 
to a consensus lists through multiple rounds of telephone conference call discussions.  
  
This article is protected by copyright. All rights reserved.
21 
 
Study Highlights (120 words) 
What is the current knowledge on the topic? 
While recent data supports CYP2C19 genotype-guided prescribing of antiplatelet therapy following 
percutaneous coronary intervention and genetic testing is increasingly deployed in clinical practice, 
pharmacogenomic testing programs are challenging to implement.  
What questions did this study address? 
What are the common challenges, pathways to operationalization, initial performance metrics, and 
lessons learned among 12 sites that are early adopters of pharmacogenomics testing?  
What does this study add to our knowledge? 
Common and differentiating features (e.g. testing approaches, how results are communicated, clinical 
decision support, provider and patient education, and methods to support the translation of emerging 
evidence to clinical practice) are presented along with a discussion of implementations challenges faced 
and lessons learned.   
How might this change clinical pharmacology or translational science? 
Disseminating the implementation experiences of early-adopters of pharmacogenomics testing provides 
valuable perspectives for those seeking to implement similar pharmacogenomics programs within their 
institutions. 
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Figure Legends 
Figure 1: Modalities of communication and education.  Approaches for providers and patients that 
were reported by sites are listed in order of decreasing scalability.   
Figure 2: Proportion of patients carrying nonfunctional alleles on alternative (ALT) therapy at 
discharge and first follow-up.  Sites using standard (single gene- and panel- based testing with >1 day 
TAT) and rapid (right panel) testing are grouped in the left and right panels, respectively.  Tables below 
indicate number of patients in each group. * p < 0.0001 by Chi-square. 
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Institution Year of  Launch Model 
Leadership (shaded) 
and collaborators* (X) Testing Mode Indication for testing 
Approx 
# PCI 
per yr^ 
Test ordering process 
Vanderbilt University 2010 Clinical 
X X X X X X X 
Reactive and 
Preemptive 
PCI and/or high clinical risk of future 
need for clopidogrel (predictive model) 
2000† 
 
Unchecked orderable 
on post-PCI order set 
University of North Carolina 
at Chapel Hill 
2012 Clinical 
 X X  X   
Reactive PCI for ACS or stable CAD  
(with high-risk anatomic findings) 
600 Unchecked orderable 
on post-PCI order set 
University of Florida Health, 
Shands Hospital, Gainesville 
2012 Clinical 
X X X  X X X 
Reactive PCI for ACS or stable CAD 400 Pre-checked on the 
post-PCI order set 
University of Illinois at 
Chicago 
2014 Research 
X X X  X X  
Reactive PCI for ACS or stable CAD  
(with high-risk anatomic findings) 
100 Research protocol 
University of Pennsylvania 2014 Research X X X  X X  Reactive PCI for ACS or stable CAD 800 Research protocol 
Indiana University 2014 Research 
X X X X X X X 
Reactive and 
Preemptive‡ 
Prescribed a targeted medication 1000† Research protocol 
 
Icahn School of Medicine at 
Mount Sinai and the Mount 
Sinai Hospital 
2014 Research 
X  X X X X  
Preemptive Future need for clopidogrel or other PGx 
meds (predictive model) 
N/A Research protocol 
 
Sanford Health 2014 Clinical 
 X X X X X  
Reactive PCI for ACS or stable CAD 600 Unchecked orderable 
on post-PCI order set 
University of Pittsburgh, 
UPMC Presbyterian Hospital 
2015 Clinical 
X X X  X X X 
Reactive PCI for ACS or stable CAD  
(with high-risk anatomic findings) 
750 Pre-checked post-PCI 
order set 
University of Alabama at 
Birmingham 
2015 Clinical 
X X X  X X X 
Reactive PCI for ACS or stable CAD  
(with high-risk anatomic findings) 
1000 Unchecked orderable 
on post-PCI order set 
University of Florida Health, 
Jacksonville 
2016 Research 
X X   X X X 
Reactive and 
Preemptive 
PCI for ACS or stable CAD; Left heart 
catheterization with intent for PCI 
1200 Research protocol 
University of Maryland, 
Baltimore 
2016 Clinical 
X X X  X X  
Reactive PCI for ACS or stable CAD 550 Unchecked orderable 
on post-PCI order set 
*Collaborators that played a key role in the design of the implementation. Gray-shaded indicates who initiated and led the effort. CTSI = Clinical and 
Translational Sciences group; ^Meeting institution criteria for CYP2C19 testing, †includes all for the panel testing, not just CYP2C19–clopidogrel. ‡Reactive for 
the initial drug and preemptive for rest of panel. 
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Table 2: Pharmacogenomic testing 
Institution Gene(s) tested Platform CYP2C19 Alleles reported 
University of Alabama at 
Birmingham 
CYP2C19 only Spartan RX, Spartan Biosciences 
(Ottawa, ON) 
*2, *3, *17 
University of Pennsylvania CYP2C19 only Spartan RX, Spartan Biosciences 
(Ottawa, ON) 
*2, *3, *17 
University of Florida Health, 
Jacksonville 
CYP2C19 only Spartan RX, Spartan Biosciences 
(Ottawa, ON) 
*2, *3, *17 
University of Illinois at 
Chicago 
CYP2C19 only eSensor XT-8, GenMark Diagnostics 
(Carlsbad, CA) 
*2, *3, *4, *5, *6, *8, *9, 
*10, *13, *17 
University of Florida Health, 
Shands Hospital, Gainesville 
CYP2C19 only* eSensor XT-8, GenMark Diagnostics 
(Carlsbad, CA) 
*2, *3, *4, *5, *6, *8, *9, 
*10, *13, *17 
University of Pittsburgh, 
UPMC Presbyterian Hospital 
CYP2C19 only eSensor XT-8, GenMark Diagnostics 
(Carlsbad, CA) 
*2, *3, *4, *5, *6, *7, *8, 
*9, *10, *17 
University of North Carolina 
at Chapel Hill 
CYP2C19 only Custom Taqman assay, 
ThermoFisher (Waltham, MA) 
*2, *3, *17 
University of Maryland, 
Baltimore 
CYP2C19 only Custom Taqman assay, 
ThermoFisher (Waltham, MA) 
*2, *3, *4, *6, *8, *17 
Sanford Health CYP2C19 only BeadXpress ADME Panel, Illumina 
(San Diego, CA) 
*2, *3, *4, *5, *6, *8, *12, 
*17 
Indiana University Panel Custom Taqman assay, 
ThermoFisher (Waltham, MA) 
*2, *3, *4, *4B, *6, *8, *10,  
*17 
Icahn School of Medicine at 
Mount Sinai and the Mount 
Sinai Hospital 
Panel MassARRAY, Agena Biosciences (San 
Diego, CA) 
*2, *3, *4, *5, *6, *7, *8, 
*17 
Vanderbilt University Panel Custom QuantStudio assay, 
ThermoFisher (Waltham, MA) 
*2, *3, *4, *5, *6, *7, *8, 
*17 
*Initially launched with multi-gene panel based testing, but changed to CYP2C19 testing only after the first year 
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Table 3: Reporting of CYP2C19 genotyping results and education strategies 
Institution 
How are 
results stored 
in the EHR? 
Is there a 
designated 
clinician/ 
service to 
respond to 
results? 
How are therapy 
recommendations 
communicated? 
Are 
there 
CDS 
alerts
? 
Are results 
actively and 
routinely 
provided to 
external 
providers?* 
Are results  
actively and 
routinely 
provided 
to 
patients? 
Provider Education 
Strategy deemed most 
successful 
University of Alabama at 
Birmingham 
In lab section 
(discrete results) 
Yes Pharmacogenomics research group 
communicates with cardiologist; 
EHR messaging; 
Yes No No Focused meetings with 
providers; in-services; 
Grand Rounds 
University of Pennsylvania In lab section 
(discrete results) 
No Research coordinator communicates 
results to Interventionalist 
No Yes;  
By letter 
No Focused meetings 
with providers 
University of Florida Health, 
Jacksonville 
In lab section  
(text-based report) 
No Study investigator provides interpretation 
and recommendations when asked 
No No No Personal 
communication 
University of Illinois at 
Chicago 
In lab section 
(discrete results) 
Yes Pharmacist on Clinical PGx Service; consult 
notes on all patients; EHR messaging 
No No Yes; 
Letter 
Focused meetings  
with providers 
University of Florida Health, 
Shands Hospital, Gainesville 
In lab section 
 (discrete results) 
Yes Pharmacists receive genotype results and 
provide recommendations for actionable 
genotypes via EHR consult notes 
Yes No No Grand rounds; personal 
communications; report 
of data 
University of Pittsburgh, 
UPMC Presbyterian Hospital 
In lab section 
(discrete results) 
Yes Pharmacist on Clinical PGx Service; consult 
notes on all patients; EHR messaging 
Yes No No Focused meetings 
with providers 
University of North Carolina 
at Chapel Hill 
In lab section 
(discrete results) 
No Pharmacist communicates with 
Interventionalist; EHR documentation 
No Yes No In-services 
University of Maryland, 
Baltimore 
In lab section (text-based 
report); in problem list 
(discrete results) 
Yes EHR messaging by multidisciplinary team; 
Elective PGx service consultation 
Yes Yes; 
By letter 
Yes; genotype  
card and after 
visit summary 
Personal 
communication 
Indiana University In lab section (discrete 
results); in problem list 
(discrete results) 
No Service, consultation notes;  
EHR messaging 
Yes No No Continual training 
model (in-services) 
Icahn School of Medicine at 
Mount Sinai and the Mount 
Sinai Hospital 
In lab section  
(text-based report) 
No CDS in EHR Yes No No Training sessions; CDS 
documents 
Sanford Health In lab section 
(discrete results) 
No CDS in EHR Yes No No In-services 
Vanderbilt University In lab section (discrete 
results); in problem list 
(discrete results) 
Yes Pharmacist sends EHR messaging; 
CDS in EHR 
Yes No Yes; all results 
in web portal 
Grand Rounds; clinical 
pharmacist/program 
champion interactions 
*To downstream provider outside of institution (i.e., to a different EHR system 
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Table 4: Primary Implementation Challenges 
• Provider/stakeholder buy-in 
• Establishing laboratory contracts with hospital 
• EHR formatting of laboratory reports 
• Development of clinical decision support 
• Logistics of: 
o sample collection in cardiac catheterization laboratory or as an outpatient 
o location of rapid testing devices and freezers 
o getting results to appropriate providers 
o returning of results prior to patient discharge due to testing TAT  
o implementation of therapy changes after patient discharge 
o delays in therapy changes until after clinical decision alert fires in the EHR system 
o notifying patients they were tested and of their results 
• Acceptance of recommendations based on testing results 
• Number of samples that needed to be recollected (for rapid testing platforms) 
• Study design (for research implementations) 
• Patient recruitment (for research implementations) 
• Billing/reimbursement for pre-emptive testing 
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Table 5: Lessons Learned 
 Design pharmacogenomics implementation program for the health system patient population 
 Identify a physician champion and engage key stakeholders 
 Target the right patient population for preemptive testing 
 Preemptive testing reduced issues around TAT, but introduced challenges with patient identification 
and reimbursement 
 Engage and educate clinicians early and repeatedly throughout the implementation process 
 Partner with hospital informatics to create clinical decision support tools and solve ongoing EHR 
challenges 
 A designated person or team to respond to results improves efficiency of therapy changes 
 Integrate clinical pharmacists to ensure adherence to the implementation algorithm and appropriate 
follow-up 
 Provide ongoing education programs for all health care providers 
 Learn from published experiences of early implementers, domain expert groups (CPIC) 
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